StockData
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc. (XBIO) stock

XBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/3064% below fair value
$1.61+0.12 (+8.05%)

Close on Nov 17, 2026Market cap $3.77MP/E –Yield –

Xenetic Biosciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Xenetic Biosciences's profit margin for the twelve months ending Jun 30, 2026 was -75.9%. For fiscal 2025 it was -90.1%, against -158.4% the year before. The highest annual figure on record is -47.4% in fiscal 2017.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-90.1%+68.3
FY2024Dec 31, 2024-158.4%+4.4
FY2023Dec 31, 2023-162.8%+221.1
FY2022Dec 31, 2022-383.9%+102.5
FY2021Dec 31, 2021-486.4%+2006.8
FY2020Dec 31, 2020-2493.1%+72363.5
FY2019Dec 31, 2019-74856.6%−74809.2
FY2017Dec 31, 2017-47.4%+1759.5
FY2016Dec 31, 2016-1806.9%−948.9
FY2013Dec 31, 2013-857.9%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-140.7%−24.0
Q1 FY2026Mar 31, 2026-56.6%+95.7
Q4 FY2025Dec 31, 2025-75.6%+87.0
Q3 FY2025Sep 30, 2025-49.7%+21.4
Q2 FY2025Jun 30, 2025-116.7%+58.6
Q1 FY2025Mar 31, 2025-152.2%+81.7
Q4 FY2024Dec 31, 2024-162.5%+11.8
Q3 FY2024Sep 30, 2024-71.1%+101.6
Q2 FY2024Jun 30, 2024-175.4%−13.9
Q1 FY2024Mar 31, 2024-234.0%−92.6
Q4 FY2023Dec 31, 2023-174.3%+466.9
Q3 FY2023Sep 30, 2023-172.7%+237.0
Q2 FY2023Jun 30, 2023-161.4%+392.3
Q1 FY2023Mar 31, 2023-141.4%+245.4
Q2 FY2022Jun 30, 2022-641.3%−256.5
Q1 FY2022Mar 31, 2022-409.7%+294.2
Q4 FY2021Dec 31, 2021-553.7%+239.3
Q3 FY2021Sep 30, 2021-386.8%+6134.5
Q2 FY2021Jun 30, 2021-384.8%+459.7
Q1 FY2021Mar 31, 2021-703.9%+1374.4
Q4 FY2020Dec 31, 2020-793.0%+6064.2
Q3 FY2020Sep 30, 2020-6521.3%−6580.5
Q2 FY2020Jun 30, 2020-844.5%+1809.5
Q1 FY2020Mar 31, 2020-2078.3%−2065.3
Q4 FY2019Dec 31, 2019-6857.2%–
Q4 FY2017Dec 31, 201759.3%–
Q3 FY2017Sep 30, 2017-2654.0%–
Q4 FY2016Dec 31, 2016-13.0%–

More Xenetic Biosciences figures

See a number that looks wrong?